<DOC>
	<DOCNO>NCT00331630</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , Abraxane , work different way stop growth tumor cell , either kill cell stop dividing . Lapatinib may stop growth tumor cell block enzyme need growth . Giving Abraxane together lapatinib may kill tumor cell . PURPOSE : This phase II trial study well give Abraxane together lapatinib work treat patient stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Abraxane Lapatinib Treating Patients With Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response rate , measure clinical exam image study , patient stage I-III breast cancer treat neoadjuvant Abraxane combination lapatinib . Secondary - Determine pathologic complete response rate patient treat regimen . - Correlate proliferation ( Ki67 ) , apoptosis ( cleave caspase-3 ) , angiogenesis ( vW , CD34 ) marker , measure treatment , tumor response patient . - Conduct correlative study , include epidermal growth factor receptor ( EGFR ) , HER2/neu , matrix metalloproteinases ( MMPs ) , transform growth factor ( TGF-β ) , treatment regimen assess tumor response patient . - Determine toxicity regimen patient . OUTLINE : This pilot study . Patients assign 1 2 treatment group . - Group 1 : The first 10 patient receive Abraxane IV 30 minute day 1 oral lapatinib daily day 1-21 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Group 2 : The next 20 patient receive Abraxane lapatinib ( high dose ) group 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo blood collection tumor biopsy periodically correlative biomarker study . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Clinical stage IIII disease Measurable disease define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan HER2/neu 3+ immunohistochemistry positive fluorescent situ hybridization No known brain metastases Hormone receptor status unspecified PATIENT CHARACTERISTICS : Menopausal status specify Male female Life expectancy &gt; 12 week ECOG performance status ( PS ) 01 OR Karnofsky PS 80100 % WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500 mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min LVEF ≥ 50 % measure echocardiogram MUGA scan No malignancy within past year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow retain oral medication No history allergic reaction attribute compound similar chemical biologic composition lapatinib No ongoing active infection No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No psychiatric illness social situation would preclude study compliance No uncontrolled illness No gastrointestinal ( GI ) tract disease would preclude ability take oral medication No malabsorption syndrome No requirement IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) PRIOR CONCURRENT THERAPY : No prior chemotherapy , immunotherapy , radiotherapy , hormonal therapy breast cancer No prior treatment epidermal growth factor receptor target therapy No prior surgical procedure affect absorption No prior surgery breast cancer At least 14 day since prior concurrent CYP3A4 inducer , include follow : Dexamethasone dexamethasone equivalent dose ≥ 1.5 mg/day , include follow : Cortisone ( ≥ 50 mg/day ) Hydrocortisone ( ≥ 40 mg/day ) Prednisone ( ≥ 10 mg/day ) Methylprednisolone ( ≥ 8 mg/day ) Phenytoin Carbamazepine Phenobarbital Efavirenz Nevirapine Rifampin Rifabutin Rifapentine Hypericum perforatum ( St. John 's wort ) Modafinil At least 7 day since prior concurrent CYP3A4 inhibitor , include follow : Clarithromycin Erythromycin Troleandomycin Delavirdine Ritonavir Indinavir Saquinavir Nelfinavir Amprenavir Lopinavir Itraconazole Ketoconazole Voriconazole Fluconazole ( dose 150 mg/day permit ) Nefazodone Fluvoxamine Verapamil Diltiazem Cimetidine Aprepitant Grapefruit juice At least 6 month since prior concurrent amiodarone At least 2 day since prior concurrent gastric pH modifiers* , include follow : Cimetidine Ranitidine Nizatidine Famotidine Omeprazole Esomeprazole Rabeprazole Pantoprazole Lansoprazole NOTE : *Antacids allow within 1 hour administration study drug No concurrent investigational agent No concurrent anticancer therapy , include chemotherapy , radiotherapy , immunotherapy , antitumor hormonal therapy No concurrent herbal ( alternative ) medicine No concurrent combination antiretroviral therapy HIVpositive patient Concurrent bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>